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Patrick Tan Khay-Guan YeohGastric cancer (GC) is globally the ﬁfth most common
cancer and third leading cause of cancer death. A complex
disease arising from the interaction of environmental and
host-associated factors, key contributors to GC’s high
mortality include its silent nature, late clinical presenta-
tion, and underlying biological and genetic heterogeneity.
Achieving a detailed molecular understanding of the
various genomic aberrations associated with GC will be
critical to improving patient outcomes. The recent years
has seen considerable progress in deciphering the genomic
landscape of GC, identifying new molecular components
such as ARID1A and RHOA, cellular pathways, and tissue
populations associated with gastric malignancy and pro-
gression. The Cancer Genome Atlas (TCGA) project is a
landmark in the molecular characterization of GC. Key
challenges for the future will involve the translation of
these molecular ﬁndings to clinical utility, by enabling
novel strategies for early GC detection, and precision
therapies for individual GC patients.Keywords: Cancer Genetics; Cancer Genomics; Gastric Cancer.
astric cancer (GC) is currently the third leadingAbbreviations used in this paper: CIMP, CpG island methylation pheno-
type; CIN, Chromosomal instability; EBV, Epstein-Barr virus; EMT,
epithelial-mesenchymal transition; GC, gastric cancer; GS, genome sta-
ble; Helicobacter pylori, H pylori; HDGC, hereditary diffuse gastric cancer;
IM, intestinal metaplasia; lincRNAs, long intergenic noncoding RNAs;
miRNAs, microRNAs; MSI, microsatellite instability; NGS, next-generation
sequencing; sCNAs, somatic copy number alterations; TFs, transcription
factors; TCGA, The Cancer Genome Atlas.
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Open access under CC BY-NC-ND license.Gcause of global cancer-related death, and particu-
larly prevalent in Asia. Despite a steadily declining inci-
dence, GC still causes more than 723,000 deaths a year.1
Achieving a detailed molecular understanding of GC patho-
genesis is pivotal to improving patient outcomes for this
complex disease. This is clearly exempliﬁed by the TOGA
Phase III trial, where GC patients with HER2/neu receptor
tyrosine kinase (RTK)-positive tumors experienced clinical
beneﬁt from chemotherapy plus trastuzumab (a HER2-
targeting antibody) relative to chemotherapy alone.2 In
this review, we have attempted to capture the latest ad-
vances in GC molecular genetics. Special attention is paid to
the recent landmark TCGA study, where almost 300 GCswere simultaneously proﬁled on multiple molecular plat-
forms to identify 4 genomic subtypes: CIN (chromosomal
instability), MSI (microsatellite instability), GS (genome
stable), and EBV (Epstein-Barr virus).3 The comprehensive
nature of the TCGA study provides an invaluable resource
upon which to interpret other related GC ﬁndings.Gastric Premalignancy and the Critical
Role of Inﬂammation
The human stomach consists of the fundus, corpus or
body, and pyloric antrum. The gastric mucosa contains three
main types of glands: cardiac glands (containing mucus-
producing foveolar cells), oxyntic glands (parietal cells and
chief cells producing hydrochloric acid and pepsinogen
respectively), and pyloric glands with mucus–secreting cells
and endocrine G cells secreting gastrin. Chronic atrophic
gastritis and intestinal metaplasia (IM) involving the gastric
mucosa are considered important steps in GC pathogenesis
(Figure 1).4 Mucosal atrophy is characterized by loss of
glandular elements and replacement by metaplastic cells or
ﬁbrosis, with concomitant hypochlorhydria. IM is a pre-
neoplastic lesion characterized by transformation of the
gastric mucosa into an intestinal-like phenotype, replete
with goblet cells and intestinal mucins. IM, associated with
Figure 1. Cause and pathogenesis of intestinal-type GC. A summary of current knowledge of the cause and pathogenesis of
intestinal type GC is shown, including host and environmental factors as well as acquired molecular events.52,143–145 GC,
gastric cancer.
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CDX2,5 is currently classiﬁed into three subtypes: intestinal
type, gastric type, and mixed gastric-intestinal type. The
latter, also known as incomplete IM, is considered to confer
the highest risk for GC development. Injury to the gastric
mucosa has also been observed to cause metaplastic
changes with spasmolytic peptide expression. This phe-
nomena, termed spasmolytic peptide expressing metaplasia
(SPEM) or trefoil factor family 2 (TFF2) expressing meta-
plasia, is induced after Helicobacter pylori (H pylori) infec-
tion and chronic gastritis.6 Spasmolytic peptide expressing
metaplasia has also been implicated as a precursor event in
GC progression.7
In most patients, frank GC is often preceded by several
decades of chronic gastric mucosal inﬂammation. Chronic
inﬂammation activates the NF-kB transcription factor, a key
mediator of tumor promotion.8 Chronic inﬂammation also
causes increased oxidative stress, due to reactive oxygen
species and nitrosamines generated by leukocytes and mac-
rophages which can damage proliferating cells. Moreover, the
production of chemokines and cytokines may induce not only
leukocyte migration but also promote carcinogenesis. Exper-
imentally,micewith impaired immune systems such as severe
combined immune deﬁciency (SCID) or recombinase
activating gene (RAG2)-deﬁcient mice are very susceptible to
H pylori infection, but do not develop signiﬁcant gastric dis-
ease.9 Such data further supports an important functional role
of the host immune system in GC pathogenesis.
Cause and Epidemiology of Gastric
Cancer
Environmental factors play critical roles in GC patho-
genesis, with major risk factors being H pylori infection, dietand smoking.10 High salt intake, often due to traditional
diets containing salted ﬁsh, is the best documented dietary
risk factor for atrophic gastritis.11 Recent data also suggests
that iron deﬁciency may be a GC risk factor, as iron deple-
tion can accelerate the progression of carcinogenesis by
augmenting H pylori virulence.12 EBV infection is recognized
as an etiological agent in 5%–10% of GCs.13,14
H pylori is the most signiﬁcant environmental risk factor
for GC and is recognized as a class I carcinogen by the
World Health Organization. Although more than 50% of the
world population is infected with H pylori, only 1%–2% of
infected people will develop GC in their lifetime.15 A major
H pylori virulence factor is the cytotoxin-associated gene A
(CagA), within the bacterial cag pathogenicity island (cag-
PAI) which is injected into the cytoplasm of gastric
epithelial cells upon microbial colonization.16 In transgenic
mice, systemic expression of CagA has been shown to
induce gastric epithelial hyperplasia, gastric polyps, gastric
and intestinal adenocarcinomas.17 Genetic variations in
CagA, speciﬁcally present in Asian strains but not non-Asian
strains, are also associated with increased chronic gastritis,
gastric ulcer and gastric adenocarcinoma in human pa-
tients.18 In gastric epithelial cells, CagA undergoes tyrosine
phosphorylation by Src kinase and activates SHP-2 (Src
homology 2- containing tyrosine phosphatase). Activated
SHP-2 induces the Ras-ERK pathway, a key regulator of cell
growth, migration, and adhesion.19 CagA also disrupts tight
junctions20 and can target the PAR1/MARK kinase to alter
apical-basolateral cell polarity, ultimately causing disorga-
nization of the gastric mucosal architecture.21 CagA also has
tyrosine phosphorylation-independent functions, including
interactions with the Met tyrosine kinase and E-cadherin.
This latter interaction disrupts binding between E-cadherin
and b-catenin, leading to nuclear accumulation of b-catenin
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transcription.22
Several clinical studies have evaluated the utility of H
pylori eradication for GC prevention. Randomized trials in
high risk populations have suggested that H pylori eradica-
tion is most effective in patient subgroups where prema-
lignant lesions have not yet developed.23 For example, a H
pylori eradication program in Matsu Island, Taiwan showed
that eradication reduces the incidence of atrophic gastritis
and peptic ulcer but not intestinal metaplasia.24 In a meta-
analysis of 6 randomized controlled trials, H pylori eradi-
cation reduced the risk of developing GC by RR of 0.65 (95%
CI, 0.43–0.98).25 In Japan, which has high rates of GC
prevalence and H pylori infection, the national health in-
surance system approved eradication therapy for H pylori-
related chronic gastritis in 2013.26
Smoking has been associated with a 1.5–2.5 fold
increased risk of GC in both case-control and cohort studies,
and this risk increases with the frequency and duration of
smoking. Studies have reported that smokers have higher
hazard ratios (HR) of GC in the cardia (HR, 2.86–4.10)
compared to distal portions of the stomach (HR,
1.52–1.94).27 Carcinogens in tobacco smoke, notably nitro-
samines and other nitroso compounds, may exert mutagenic
effects, thereby increasing GC risk.28 Smoking also increases
the risk for precancerous lesions such as intestinal meta-
plasia and dysplasia.29
EBV has been detected in 5%–10% of GC.13,14 A meta-
analysis of 70 studies including 15,952 cases of GC
demonstrated that EBV-associated GC predominantly arises
in men and is found in cardia and body sites more often
than in the antrum.14 A major molecular feature of EBV-
associated GCs is CpG island promoter methylation of
cancer-related genes.30 Expression of EBV viral latent
membrane protein 2A (LMP2A) may be responsible for the
promotion of DNA methylation, by inducing STAT3 phos-
phorylation and subsequent transcription of DNA methyl-
transferase 1 (DNMT1). EBV also encodes a large number of
microRNAs (miRNAs),31 mostly encoded in the BHRF1 and
BART regions of the genome. EBV miRNAs can repress
cellular proteins, including p53 up-regulated modulator of
apoptosis (PUMA), DICER1, and BIM.32 A recent study
proﬁling 44 known EBV miRNAs in clinical samples from
EBV-associated GC patients found that EBV-miR-BART4-5p
plays an important role in gastric carcinogenesis through
regulation of apoptosis.33Gastric Cancer Host Genetics
Besides environmental agents, GC pathogenesis also in-
volves host genetic factors. One of the ﬁrst host genetic
factors identiﬁed in GC involved polymorphisms in the
proinﬂammatory gene interleukin 1-b (IL-1 b).34 A more
recent study reported that combinations of single nucleotide
polymorphisms (SNPs) in immune-related genes [inter-
leukin 1-b (IL-1 b), interleukin 1 receptor antagonist
(IL-1RN), tumor necrosis factor- a (TNF- a) and interleukin
10 (IL-10)] conferred a manifold increased risk of devel-
oping GC, but only in H pylori infected patients.35Furthermore, a combination of high-risk host genotypes
and high-risk H pylori genotypes greatly increased the
probability of GC, up to 87-fold over baseline. These studies
highlight again the critical role of host immunity in deter-
mining GC outcomes following H pylori infection.36 Certain
high risk GC genotypes may differ in different populations,
for example, a meta-analysis showed Asian high risk SNPs
differ from those identiﬁed in the non-Asian population.37
Another identiﬁed host genetic factor for GC is prostate
stem cell antgen (PSCA), which inﬂuences susceptibility to
diffuse-type GC and may play a role in gastric epithelial cell
proliferation.38 PSCA genetic variants have also been
recently conﬁrmed as inﬂuencing GC in a wide variety of
populations.39
Hereditary GC syndromes are rare and account for 1-3%
of GC, comprising mainly three types: hereditary diffuse
gastric cancer (HDGC), gastric adenocarcinoma and prox-
imal polyposis of the stomach (GAPPS) and familial intesti-
nal gastric cancer (FIGC).40 HDGC is due to E-cadherin
(CDH1) germline mutations,41 and patients with this con-
dition are often managed with prophylactic gastrectomies.41
Besides CDH1, other recently identiﬁed candidate HDGC
genes include CTNNA1, BRCA2 and STK11.42 GAPPS, ﬁrst
reported in 2012, is characterized by autosomal dominant
transmission of fundic gland polyposis (including dysplastic
lesions or adenocarcinoma or both) restricted to the prox-
imal stomach with no evidence of colorectal/duodenal pol-
yposis or other hereditary gastrointestinal cancer
syndromes.43 Its genetic cause is as yet unknown. GC has
also been associated with other hereditary cancer syn-
dromes such as Lynch syndrome, hereditary nonpolyposis
colorectal cancer syndrome, familial adenomatous polypo-
sis, and Li-Fraumeni syndrome.40Gastric Cancer Pathology
GC is morphologically, biologically, and genetically het-
erogeneous. Most GCs are adenocarcinomas, with lym-
phoma, sarcomas, and carcinoids comprising less than 5%.
Adenocarcinomas are grouped by the Lauren classiﬁcation
into intestinal and diffuse types.44,45 In intestinal type tu-
mors, the malignant cells form gland-like structures, unlike
those in diffuse type tumors. Intestinal type GC is more
common in high-risk regions while diffuse type GC is more
common in low-risk areas. Diffuse type GC is more common
in young patients, in whom there is a female preponder-
ance,45 and behaves more aggressively than the intestinal
type.46 Besides the Lauren classiﬁcation, other histopatho-
logical classiﬁcations for GC have been proposed. For
example, the WHO classiﬁcation groups GC into 4 main
types based on the predominant histological pattern:
tubular, papillary, mucinous and signet ring cell.47Molecular Genetic Landscape of
Gastric Cancer
Studies from several groups over the past decade have
now produced a near-comprehensive catalogue of GC-
associated “driver” alterations, including gene mutations,
Figure 2.Genomic fea-
tures of GC, inspired by
the classic Hallmarks of
Cancer report by Hanahan
and Weinberg.146 Details
of each genomic feature
are provided in the text.
GC, gastric cancer.
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ants, epigenetic changes, and transcriptional changes
involving mRNAs and noncoding RNAs (ncRNAs) (Figure 2).
Certain driver alterations can also be associated with spe-
ciﬁc GC subtypes. For example, MSI is a genetic hypermu-
tability phenomenon where microsatellite regions in tumor
genomes accumulate mutations due to defective DNA
mismatch repair. Next-generation sequencing (NGS) studies
have shown that 15%–20% of GCs are characterized by MSI.
For ease of presentation, our review has been structured to
summarize each molecular level independently.Gene Mutations in Gastric Cancer
Like most solid epithelial cancers, GCs are often char-
acterized by somatically-acquired mutations in various
genes. Current estimates based on NGS indicate that in each
individual GC (excluding hypermutated cases), there are
approximately 50 to 70 nonsynonymous mutations, a mu-
tation level comparable to colon and esophageal cancer.48
Mutated genes in GC can be broadly classiﬁed into three
categories: a) high-frequency drivers displaying a high-rate
of recurrence (>5%–10%) across multiple GCs; b)
low-frequency drivers that are recurrently mutated in the
1%–10% range, but which still contribute to disease path-
ogenesis; and c) bystander/passenger mutations that arise
as a consequence of underlying mutational processes such
as CpG deamination,49 but which do not functionally
contribute to tumorigenesis.
Among high-frequency drivers, TP53 is the most
frequently mutated gene in GC, exhibiting aberrations in
w50% of cases.50 Reﬂecting TP53’s cellular function as a
guardian of genomic integrity, TP53 mutated GCs often
exhibit high levels of sCNAs3,51 involving both broadchromosomal regions and focal gene regions. GCs have
also been shown to exhibit mutations in other canonical
oncogenes (KRAS, CTNNB1, PIK3CA) and tumor suppressor
genes (SMAD4, APC).52 Reﬂecting the importance of RTK/
RAS/MAPK signaling in GC, frequent mutations in the
ERBB3 RTK and the ligand/RTK NRG1/ERBB4 genes have
recently been reported.53,54 Some of these mutations
appear to be enriched in speciﬁc GC subtypes, for example,
EBV-positive GCs frequently exhibit PIK3CA mutations,3
while diffuse-type GCs have been observed to exhibit
frequent somatic mutations in CDH1.55
Recent NGS studies of GC have also highlighted two new
GC genes - ARID1A and RHOA. ARID1A, mutated in 10%–15%
of GCs,56,57 encodes a component of the SWI/SNF chromatin
remodeler complex. ARID1A mutations in GC are typically
inactivating (eg, frameshifts, nonsensemutations), consistent
with ARID1A acting as a tumor suppressor. Functional anal-
ysis suggests that ARID1A plays a role in GC cell proliferation,
through the control of cell-cycle regulators CCNE1 and
E2F1.57 RHOA was recently shown by multiple studies to
exhibit recurrent mutations in diffuse-type/genome-stable
GCs.3,55,58 Unlike ARID1A where mutations are dispersed
throughout the gene, the RHOAmutations are localized to an
N-terminal hot-spot region (Tyr42, Arg5 and Gly17), and are
predicted tomodulate downstream Rho signaling. Functional
analysis of these RHOA mutations suggest that they may
impart resistance to anoikis, a form of programmed cell death
occurring after cellular detachment from a solid substrate.55
Clinically, the discovery of RHOA hot-spot mutations is
particularly exciting, as it provides an inroad for the devel-
opment of new approaches to target diffuse-type GCs, tradi-
tionally associated with extremely poor prognosis.
Besides high-frequency driver mutations, genomic
studies have also uncovered a “long tail” of low frequency
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BCOR (encoding a BCL6 corepressor), FAT4 (a proto-
cadherin), and RNF43, a Wnt pathway regulator.3,55,57
Despite their lower mutation frequencies, these genes also
likely contribute to the ability of GCs to manifest different
cancer hallmarks. For example, mutations in the antigen-
presenting genes HLA-B and B2M, observed in MSI-
positive GCs, may play a role in evading host anti-tumor
immune responses arising from the presentation of tumor
neo-antigens.3 A key challenge for the GC ﬁeld will be to
develop systematic, high-throughput approaches to func-
tionally test the effects of these mutations, either singly or in
combination, on the GC cell.
NGS analyses of GCs, particularly at the whole-genome
level, are also providing insights into prominent pathways
and mutation signatures associated with GC develop-
ment.55,59,60 For example, when all mutated genes (regard-
less of driver status) are considered in a collective pathway
analysis, cell adhesion and chromatin remodeling are
consistently highlighted as the top major disrupted path-
ways.56,57 Emerging evidence suggests that these processes
are likely to be disrupted even in premalignant gastric tis-
sues and early GC.61,62 A survey of mutational “signatures”,
referring to mutations occurring in particular sequence
contexts, has highlighted speciﬁc carcinogenic and muta-
tional processes active in GC, including microsatellite
instability, CpG age-associated deamination, and the acti-
vation of cytidine deaminases such as AID and
APOBEC3B.63–65 Emerging studies are now being performed
to study patterns of GC tumor evolution and clonality,
occurring either within the primary tumor, or between
primary lesions and metastatic sites.54,66 Such results will
be crucial for identifying molecular events associated with
GC progression rather than initiation, and may suggest
improved strategies for managing patients with advanced
metastatic GC.
sCNAs and Structural Variation in
Gastric Cancer
sCNAs are another major mechanism by which onco-
genes and tumor suppressor genes are selectively activated
or inactivated in GC. Several studies have reported genome-
scale analyses to identify GC genes affected by sCNA,67,68
highlighting speciﬁc genes targeted by this mechanism.
The most predominant class of genes frequently ampliﬁed
in GC are those related to RTK/RAS/MAPK signaling,
including HER2, EGFR, MET, FGFR2, and RAS genes (KRAS,
and to a lesser extent NRAS).3,67 In total, about 30%–40% of
GCs are likely to harbor a RTK/RAS/MAPK-related ampliﬁ-
cation, and therapies targeting these genes are in clinical
trials, including trastuzumab (HER2), nimotuzumab (EGFR),
AZD4547 (FGFR2), and onartuzumab (MET) (Table 1).
Another gene frequently ampliﬁed in GC that may intersect
with the canonical RTK/RAS/MAPK pathway is VEGFA, a
mediator of angiogenesis that is particularly noteworthy
given the role of anti-angiogenic therapy in GC.69 In the
TCGA study, EBV-positive GCs were also found to harbor
frequent ampliﬁcations in PD-L1 and L2, which are immunecheckpoint inhibitor genes, and are of particular relevance
as targets of immunotherapy.3
Another class of genes targeted by gene ampliﬁcation in
GC are related to cell cycle control, including CCND1, CCNE1,
and CDK6. These cell-cycle genes are clinically relevant in
two capacities. First, direct therapies are available for tar-
gets such as CDK6, while CCND1 and CCNE1, which encode
cyclin subunits, may also be targetable through their
cognate CDK partners (CDK4/6 for CCND1, CDK1/2 for
CCNE1). Second, coampliﬁcation of these cell-cycle regula-
tors with other therapeutic targets, particularly those in the
RTK/RAS/MAPK pathway, may modulate responses to the
therapies targeting the latter. For example, CCNE1 ampliﬁ-
cations frequently occur together with HER2 ampliﬁca-
tions,67,70 a conﬁguration that has been linked to acquired
trastuzumab resistance in breast cancer.71 HER2/CCNE1
coampliﬁcation has recently been validated as a mechanism
of primary resistance against lapatinib (a dual EGFR/HER2
inhibitor) in HER2-ampliﬁed GC.70 Knowledge of the
ampliﬁcation status of these cell-cycle related genes in in-
dividual GCs may thus further improve our ability to stratify
patients in clinical trials employing targeted agents.
A third class of GC-ampliﬁed genes corresponds to those
involved in transcriptional regulation, such as GATA factors
(GATA4, GATA6), KLF5, and MYC. Ampliﬁcations of GATA
factors and KLF5 appear to be restricted to gastrointestinal,
and possibly related hepatobiliary malignancies.72,73 These
transcription factors (TFs) are expressed in the developing
and normal stomach,74 and may act as “lineage-survival”
factors functioning to reawaken early developmental pro-
grams to drive GC tumorigenesis. Interestingly, recent
chromatin immunoprecipitation (ChIP) sequencing studies
provide evidence that these ampliﬁed TFs, may in fact
collaborate with one another to regulate common down-
stream promoters in genes associated with GC develop-
ment.73 Another transcription factor ampliﬁed in GC is
OCT1, a regulator of ERK signaling.75 Although traditionally
considered to be “undruggable” by the pharmaceutical in-
dustry, novel chemical biology technologies for disrupting
such oncogenic TFs are in development.76
Besides ampliﬁcations, genomic deletions also
frequently occur in GC, involving tumor suppressor genes
such as WWOX, RB1, PARK2, FHIT, and CDKN2A/B.67 So-
matic deletions in CDH1 have been associated with poor
patient prognosis,77 and genomic deletions involving
nonprotein coding genes such as mir-101a have been re-
ported, which can cause upregulation of the oncogenic his-
tone methyltransferase EZH2.78 Interestingly, while most
genomic deletions are often interpreted as loss-of-function
events, a recent study has shown that the phosphodies-
terase PDE4D, frequently targeted by microdeletions in
several cancers including GC, is associated with a constitu-
tively active PDE4D isoform that promotes tumor growth.79
It is thus possible that, as sequencing technologies improve,
detailed ﬁne mapping of genomic deletion break-points will
highlight similar unexpected examples, prompting the
revisiting of these “deleted” genes as tumor suppressors.
Genomic rearrangements, either balanced or associated
with copy number changes, can also result in fusion genes,
Table 1.GC Genomic Alterations as Therapeutic Targets
Gene Alteration Prevalence in GCa Representative Therapies Clinical Statusb
ERRB2 Ampliﬁcation/overexpression 10%–20% Traztuzumab/trastuzumab
emtansine
Approved/Phase III
VEGFR2 Overexpression w50% Ramucirumab Approved
VEGF Overexpression 40%–50% Bevacizumab/regorafenib Phase III (negative)/phase II
EGFR Ampliﬁcation/overexpression 6%–27% Cetuximab/nimotuzumab Phase II/III
MET Ampliﬁcation/overexpression 5%–40% Onartuzumab/AMG337 Phase II/III
FGFR2 Ampliﬁcation/overexpression 4%–12% AZD4547/dovitinib Phase II
ATM Loss (Protein) 60% Olaparib Phase III
PIK3CA Mutation 5%–10% Everolimus/GDC0068 Pre-clinical/early trials
CDK4/6 Ampliﬁcation 6%–15% LEE001 Phase II
PD-L1/L2 Ampliﬁcation/overexpression 15% of EBV-positive GC MPDL3280A Preclinical/phase I
MSI Mutation 15%–20% Pembrolizumab (anti-PD1) Phase II
ARID1A Mutation 8%–10% EZH2 inhibition Preclinical
GC, gastric cancer; EBV, Epstein-Barr virus; MSI, microsatellite Instability.
aPrevalence rates incorporate data based on both genomic alterations and protein immunohistochemistry.
bMost ongoing trials do not involve biomarker-selected GC patients.
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in chronic myelogenous leukemia), or causing high expression
of one gene through hijacking of the partner’s promoter (eg,
TMPRRS2-ERG in prostate cancer). An RNA-sequencing study
in 2010 revealed for the ﬁrst time the presence of rare RAF-
fusion genes in GC and prostate cancers (eg, AGTRAP-BRAF),
and preclinical models expressing these RAF fusions were
shown sensitive to treatment by soraﬁnib, originally designed
as a RAF inhibitor.80 The second fusion gene identiﬁed in GC
was CD44-SLC1A2, which juxtaposes the SLC1A2 glutamate
transporter against the CD44 promoter.81 Tumors expressing
this gene fusion expressed high levels of SLC1A2 which may
facilitate the acquisition of glutamate by the cancer cell to fuel
cancer metabolism. Subsequently, CD44-SLC1A2 and related
APIP-SLC1A2 fusions have been observed in colon cancer,
indicating that such fusions may be restricted to
gastrointestinal-type cancers.82,83 ROS1 rearrangements in GC
have been recently reported,84 and in the TCGA study,
CLDN18-ARHGAP26 fusions were observed in genome-stable/
diffuse type GC. Interestingly, ARHGAP26 is a member of the
Rho-effector pathway, and the CLN18-ARHGAP26 fusions are
mutually exclusive to RhoAmutations and CDH1mutations, all
pointing to a common dependence on cell-adhesion related
Rho signaling in diffuse-type GC.3 Indeed, recent functional
data has conﬁrmed that CLDN18-ARHGAP26 expression in
epithelial cells can reduce cell-cell and cell-extracellular ma-
trix-adhesion, while contributing to epithelial-mesenchymal
transition (EMT).85 Taken collectively, these examples attest
to the presence of gene fusions in GC, which due to their
cancer-speciﬁc nature, may be exploited for improved di-
agnostics or therapeutics.
Epigenetic Alterations involving DNA
Methylation and Chromatin
Epigenetic aberrations are also emerging as important
players in GC pathogenesis. These can occur at the level of
DNA methylation, where methyl groups are attached to
cytosine bases at CG motifs; or histone modiﬁcations wherespeciﬁc residues in histones are methylated, acetylated, or
phosphorylated. There is great interest in studying how
environmental risk factors for GC may modulate the gastric
epigenome. For example, H pylori has been shown to infect
and induce widespread DNA methylation changes in stom-
ach epithelial cells.86 Such “epigenetic ﬁeld defects” are
likely to contribute to an individual’s risk of developing GC.
The epigenetic ﬁeld model has recently been supported by a
recent prospective clinical trial.87
There is a rich body of GC literature relating promoter
DNA methylation to the transcriptional silencing of tumor
suppressor genes (CDH1, RUNX3, p16, and hMLH1).88
Alterations in DNA methylation can also inﬂuence GC pro-
gression and treatment response. For example, methylation-
associated silencing of PLA2G2A, a secreted phospholipase,
may play a role in driving aggressive GC,89 and methylation
of SULF2 and BMP4 have been linked to chemotherapeutic
responses.90,91 Beyond individual genes, genome-wide
studies have also revealed large scale patterns of DNA
methylation in GC. Multiple studies have conﬁrmed that
certain GCs can exhibit a CpG island methylation phenotype
(CIMP), characterized by genome-wide methylation of CpG
islands.92–94 Patients with CIMP type GCs tend to be
younger, with less-differentiated tumors. Pathway analysis
reveals that genes targeted by CIMP in GC are enriched in
genes corresponding to PRC2-targets in embryonic stem
cells, suggesting a reawakening in CIMP tumors of a nascent
stem cell program. Interestingly, in preclinical assays, CIMP-
positive GCs appear to exhibit heightened sensitivity to DNA
methyltransferase inhibitors such as 5’aza.93
As described by earlier studies and conﬁrmed by TCGA,
EBV-positive GCs also exhibit exceptionally high DNA
methylation levels,3,30 Indeed, among all tumor types stud-
ied by TCGA to date, EBV-positive GCs appear to exhibit the
highest DNA methylation levels, surpassing even CIMP tu-
mors. It is possible that such hypermethylation may repre-
sent a cellular reaction to viral infection. Emphasizing
the importance of tumor immunity in this GC subtype,
EBV-positive GCs also typically exhibit a high lymphocytic
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PD-L1 and PD-L2 ampliﬁcation. Another recent study has
recently reported additional mutated genes in EBV-positive
GC, which may contribute to tumor neo-antigen formation in
this unique and intriguing cancer subtype.96
In contrast to DNA methylation, our understanding of
histone modiﬁcations in GC is still embryonic. An earlier
study assessing patterns of the H3K37me3 repressive mark
found over a hundred genes exhibiting H3k27me3 differ-
ences between GCs and matched normal tissues.97 More
recently, a study employing a nano-scale chromatin immu-
noprecipitation techniques to proﬁle multiple histone marks
in GCs and matched normal tissues,98 found evidence of
widespread alternative promoter usage and deregulated
enhancer elements, including an alternative isoform of the
MET RTK that produces a MET protein variant lacking the
SEMA N-terminal regulatory domain. Future work will be
focused on understanding the mechanisms underlying such
regulated regulatory elements, and how they might be
harnessed for predictive or prognostic potential.
Gastric Cancer Transcriptome—Gene
Signatures and Alternative Splicing
Altered regulation of gene expression programs are
critical to the ability of tumors to express different cancer
hallmarks. In early 2000, early microarray studies already
revealed a staggering diversity of expression programs
operative in GC, associated with different histological sub-
types, tumor status, and clinical traits.99–101 In the past
decade, groups have deployed more mature transcriptomic
technologies, on larger patient cohorts, to identify robust
gene expression “signatures” that can subtype GC in a
clinically relevant fashion. Such GC transcriptome studies
have typically fallen into two categories: a) unsupervised,
where GC subtypes are discovered based on molecular data
in an unbiased fashion and then correlated to clinical data;
or b) supervised, where clinical data is directly correlated to
molecular data to identify highly associated expression
patterns. Among unsupervised studies, one report, starting
from a panel of GC cell lines, identiﬁed two “intrinsic”
subtypes of GC (G-INT/G-DIF), that when mapped to pri-
mary GCs correlated with Lauren’s classiﬁcation, and was
both prognostic and predictive to 5-FU related chemother-
apies.102 This classiﬁcation has recently been extended to
three subtypes - proliferative, mesenchymal, and metabolic,
where cell lines with mesenchymal features were found to
be more responsive to PIK3CA/mTOR inhibitor com-
pounds.51 Other unsupervised classiﬁcations have been
proposed, including a recent 4-subtype system by the Asian
Cancer Research Group (ACRG), a collaboration between
academia and industry.103 In complement to these, groups
performing supervised analyses have also reported speciﬁc
gene signatures for directly predicting GC patient prognosis.
One study reported a 6-gene signature that could be used to
compute an individualized “risk-score” for predicting GC
prognosis.104 In another study from Korea, investigators
explored expression patterns of >1000 GCs to identify an 8-
gene signature capable of predicting the prognosis of StageII GC patients.105 This is a highly clinically-relevant ques-
tion, as Stage II patients identiﬁed as “poor prognosis” by
the gene signature might be prescribed adjuvant chemo-
therapy, while “good prognosis” patients might be treated
with surgery alone.
Transcriptomic information can also be exploited as a
powerful discovery method to identify deregulated path-
ways in GC. One study exploring this approach reported that
GCs exhibiting combinations of activated oncogenic path-
ways were associated with poor prognosis relative to GCs
with activation of single pathways.106 Investigators have
also used RNA-sequencing data of GCs from different
countries to identify the AMPK/HNF4a/Wnt5a pathway as
a targetable oncogenic pathway in early stage GC.107,108
However, it should be noted that while transcriptomes are
highly dynamic, almost all GC transcriptomic studies to date
have relied upon analyzing GCs obtained at a single time-
point, usually upon surgical resection. There is thus great
interest in understanding gene expression (and other mo-
lecular) changes in GCs during temporal progression or
treatment. Demonstrating the power of this temporal
approach, one highly notable study used paired endoscopic
biopsies to study gene expression changes in GC patients
prior to and after developing resistance to 5-FU/platinum
therapies.109 They identiﬁed an acquired-resistance signa-
ture comprising genes related to cell survival (mTOR
pathway), DNA repair, and embryonic stem cell biology.
Data from such efforts, while still scanty in the literature,
will prove vital in attempts to overcome chemotherapy
resistance in GC.
Transcriptomic analysis is also revealing new molecular
features of GC biology, above and beyond those provided
through the study of DNA. One especially exciting ﬁeld of
exploration is alternative splicing, where different transcript
isoforms of the same gene may play distinct functional or
oncogenic roles. One of most famous examples of alternative
splicing in GC involves the CD44 gene, which encodes a cell-
surface glycoprotein that binds hyaluronic acid and medi-
ates a diversity of cell-cell interactions. Recent data has
revealed that GC stem cells express a speciﬁc CD44 tran-
script variant (CD44v8-10) that can be used to enrich for
tumor-initiating cells.110 Functional analysis of this variant
suggests that its role is to act as a copartner of the xCT
cysteine transporter, to regulate oxidative stress.111 Another
recent example of alternative splicing in GC, revealed
through integrated exome/transcriptome analysis, involves
the selective use of the ZAK kinase isoform TV1 in tumors,
which is required to maintain cell proliferation in experi-
mental systems.112 Alternative splicing events can also
cause production of fusion genes in the absence of genome
rearrangements, through the process of “read-through”
transcription. One example of this process is PPP1R1B-
STARD3, involving two genes adjacent to one another in the
human genome, which fuses exon 6 of PPP1R1B to exon 2 of
STARD3. Interestingly, functional analysis suggests that gene
products arising from such “read-through” fusions may be
enriched in gastric tumors related to matched normal con-
trols, and may contribute towards certain pro-oncogenic
features.113
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Non-coding RNAs represent yet another active player
in GC pathogenesis, involving different RNA classes such
as miRNAs and long intergenic noncoding RNAs (lincR-
NAs). miRNAs are small RNAs (w22 nucleotides) that can
bind to target gene transcripts to induce the latter’s
transcript or protein downregulation. Studies from mul-
tiple groups have now produced a growing list of >200
miRNAs with potential roles in GC development, pro-
gression, and treatment response.114,115 Examples of
oncogenic miRNAs include miR-21, miR-27a, and mir-
130b; which are overexpressed in GC tumors and cell
lines relative to normal controls.116,117 Oncogenic miRNAs
typically function to target and downregulate tumor
suppressor genes, for example, mir-21 has been reported
to target the tumor suppressor genes PTEN and
PDCD4,116,118 while mir-130b has been shown to regulate
RUNX3.117 Reciprocally, tumor suppressor miRNAs such
as mir-375, mir-486, mir-29c, and mir-101 are down-
regulated in GC, typically by DNA methylation or genomic
loss, and are required to silence genes with oncogenic
potential such as PDK1, OLFM4, ITGB1, and EZH2
respectively.78,119,120,121 Some miRNAs may also
contribute to GC pathogenesis by functioning as key
components of oncogenic signaling pathways, as shown
by recent data implicating mir-365 in PTEN/Akt
signaling,122 or by responding to external carcinogens (H
pylori) to stimulate cellular proliferation (eg, mir-210).123
Work is also ongoing to characterize the role of miRNAs
in tumor progression and drug resistance, with numerous
studies reporting miRNA expression patterns associated
with patient outcome.124,125 For example, miRNAs in the
mir-200 family play a key role in regulating EMT via EMT
regulators such as ZEB1, and mir-200 downregulaton is
associated with poor prognosis.126
In contrast to miRNAs, our current knowledge of the role
of lincRNAs in GC is still immature, however recent studies
examining expression of lincRNAs such as HOTAIR and
GAPLINC in GC suggest an important role for this RNA class
in GC development and progression.127,128 Identifying the
most prevalent deregulated lincRNAs in GC, and deciphering
their functional and mechanistic roles in regulating gene
expression and cancer behavior, will clearly be highly fertile
area for future GC research.Beyond the Cancer Cell: Contributions
From the Tumor Microenvironment
Gastric tumors are composed not just of cancer cells
but also other cell populations including stromal cells,
immune cells, and blood vessels. Far from being innocent
bystanders, studies are now demonstrating that these
“noncancer” compartments are also likely to play impor-
tant roles in GC disease progression and aggressiveness.
Several studies have now conﬁrmed that GCs with a high
stromal content, determined either by gene expression
analysis or histopathological evaluation, are associated
with poor prognosis.129,130 Similar ﬁndings have also beenreported in other tumor types, such as breast, lung and
esophageal cancers.131,132 The mechanisms underlying the
role of the tumor stroma in supporting GC growth are
likely multifactorial, ranging from providing a suitable
extracellular matrix to maintain cancer cell growth, active
cell-cell interactions via cancer-associated ﬁbroblasts
which can secrete growth-stimulatory molecules such as
IL-6, and providing a physical barrier inhibiting chemo-
therapy from reaching target malignant cells.133 Major
pathways implicated in the tumor stroma include TGFb
signaling and EMT-related signaling events, pointing to
complex interactions between cancer cells and their
nonmalignant neighboring cellular populations.130,133
Studies are now emerging at attempting to target the tu-
mor stroma for therapy.134
Another intra-tumor cellular population vitally
important to GC development are cells regulating tumor
vasculature and immunity. GCs have been shown to
secrete pro-angiogenic compounds such as VEGF, CXCL1,
and Ang-2 to stimulate blood vessel formation.133 In GC,
multiple clinical trials targeting various aspects of the
tumor angiogenesis axis have been conducted. In the
AVAGAST trial, the combination of bevacizumab (an
antibody targeting VEGFA) and chemotherapy did not
extend overall survival compared to patients treated
with chemotherapy alone.69 Recently however, the
RAINBOW and REGARD trials evaluating ramucirumab, a
VEGFR2-targeting antibody, reported an improvement in
overall survival in patients with advanced GC.135,136
Interestingly, for at least two of these studies (AVA-
GAST and RAINBOW), subsequent subset and biomarker
analysis revealed that GC patients from non-Asian
countries tended to receive clinical beneﬁt from the
addition of bevacizumab, compared to patients from
Asian countries. It is thus possible that GC populations in
different countries (speciﬁcally Asian and non-Asian
countries) may respond differently to anti-angiogenic
and potentially other therapies.
Finally, immune cells of many different types are also
frequently observed in primary GCs, and certain subtypes
of GC (eg, EBV-positive GC and MSI-positive GC) are well-
known to be associated with a high lymphocytic inﬁl-
trate. Depending on their speciﬁc identities and immune
functions, such tumor-inﬁltrating immune cells may play
pro- or anti-tumorigenic roles. For example, GCs with high
levels of regulatory T cells (FOXP3-positive) have been
reported to exhibit good prognosis,137 while those with
high levels of IL-17 producing CD8-positive T cells (cyto-
toxic T cells) are associated with poor prognosis.138 The
role of tumor immunity in cancer progression is extremely
broad, and readers are directed to other excellent reviews
dedicated to this subject.139 Interestingly, two recent
studies have also reported that Asian and non-Asian GC
populations may differ in their regulation of tumor im-
munity factors at the genetic and gene expression level,
which may impact region-speciﬁc effects on therapy
outcome and prognosis.140,141 Given the intimate rela-
tionship between immune cells and tumor vasculature, it
will be interesting to test if such differences might
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clinical trial outcomes, or if they may impact patient se-
lection in future trials evaluating different types of immune
checkpoint inhibitors.GE
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SConclusions and Challenges
Our knowledge of GC molecular pathogenesis has
considerably evolved over the years, but much remains
unknown. In terms of basic understanding, the role of novel
molecular entities such as lincRNAs and chromatin alter-
ations in GC remains to be unraveled. DNA sequencing
studies have also revealed a complex community of non-
cultivatable microbiota in the human stomach beyond H
pylori and EBV, and it will be critical to understand how the
gastric “microbiome” may interact with both H pylori and
the host immune response to inﬂuence gastric carcinogen-
esis.142 In the early detection ﬁeld, molecular ﬁndings may
facilitate new approaches for diagnosing GC early, by iden-
tifying high-risk individuals through the molecular charac-
terization of preneoplastic lesions or even blood-based
biomarker assays. Finally, therapeutic strategies remain to
be developed to target speciﬁc GC subtypes (particularly
diffuse type GC), based upon their somatic driver alterations
or tumor-associated cell compartments (eg, stromal cells
and tumor-inﬁltrating immune cells). The next ﬁve years
will undoubtedly see a further explosion of ﬁndings in the
GC ﬁeld, which will be essential to combat this deadly
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